PT-141 Dosage Chart: Quick Reference

The chart below pairs the FDA-approved reference with the research protocols people report using. Doses above the 1.75 mg reference do not reliably add benefit and do raise nausea and blood-pressure effects, so the ceiling is a real one, not a suggestion.

The FDA-Approved Dose: Vyleesi at 1.75 mg

Bremelanotide was approved by the FDA in June 2019 under the brand Vyleesi for hypoactive sexual desire disorder in premenopausal women. The label dose is 1.75 mg injected subcutaneously into the abdomen or thigh, taken as needed at least 45 minutes before anticipated sexual activity. Each pre-filled autoinjector delivers that fixed 1.75 mg in 0.3 mL. This is the single most reliable dosing fact for PT-141, because it comes from a regulated product with trial data behind it rather than from forum consensus.

The approval also sets hard limits: no more than one dose in any 24-hour period, and no more than 8 doses per month. Those ceilings are built around the blood-pressure and nausea profile, not around tolerance to the effect.

Research Subcutaneous Dosing

Vialed PT-141 sold for research follows the same 1.75 mg reference, but because it is self-reconstituted and self-measured, most experienced users start well below that. A common approach is a 0.5 to 1 mg test dose on a quiet evening to see how strong the nausea and flushing are, then stepping toward 1.75 mg only if the lower dose is well tolerated and underwhelming. Injection technique mirrors any other subcutaneous peptide; if you are new to it, the mechanics in how to inject BPC-157 transfer directly.

Going above 1.75 mg is where the risk-to-reward turns clearly negative. Higher doses do not deepen the desired effect meaningfully, and they push nausea and the transient pressor response up. There is no research protocol that supports routinely dosing beyond the approved reference.

Nasal Spray Dosing

PT-141 nasal spray exists only as a compounded research format. An earlier intranasal version of bremelanotide was studied and then dropped in favor of the subcutaneous route, partly because nasal absorption was harder to control and blood-pressure spikes were a concern at higher exposures. Community nasal protocols land around 1 to 2 mg per session, split across sprays, taken 45 to 90 minutes before activity. Expect more variability in onset and intensity than with an injection, since how much peptide actually crosses the nasal lining changes with congestion, technique, and formulation.

Reconstitution: Turning a Vial into a Dose

Research PT-141 ships as a lyophilized powder. Reconstitute it with bacteriostatic water, add the water slowly against the vial wall, swirl rather than shake, and refrigerate. A 10 mg vial with 2 mL of bacteriostatic water yields 5 mg/mL, so a 1.75 mg dose is 0.35 mL, or 35 units on a standard U-100 insulin syringe. Use the calculator to match your own vial size and target dose.

Storage matters for potency: keep reconstituted PT-141 refrigerated and use it within a few weeks. The general rules in our peptide storage guide apply here too.

Timing and Administration

The label minimum is 45 minutes ahead, but in practice the window is wider, often 1 to 3 hours, and the effect can outlast that. Because timing is individual, treat the first one or two doses as calibration rather than performance. Take it when there is no schedule pressure, note how long onset takes for you, and use that personal timing afterward. Eating a light meal beforehand can blunt the nausea somewhat.

Dosing in Men vs Women

The approved indication and dose are specific to premenopausal women. There is no FDA-established dose for men. Men who use research PT-141 generally borrow the same 1.75 mg reference and titrate up from a lower start because nausea scales with dose regardless of sex. Framed honestly, male use is off-label and outside the trial population, so the safety margins studied for Vyleesi do not automatically carry over.

Side Effects and Safety Limits

Nausea dominates the side-effect profile and is dose-related; it affected roughly 40 percent of patients in the Vyleesi trials and drove most discontinuations. Flushing, headache, and injection-site reactions are common. Every dose produces a transient rise in blood pressure and a fall in heart rate, usually peaking within hours and resolving on its own, which is the reason PT-141 is contraindicated in uncontrolled hypertension and known cardiovascular disease. Frequent use can cause focal hyperpigmentation of the face, gums, or breasts through melanocortin activity. The 8-doses-per-month ceiling is a safety limit, not a starting point to work up from.

Common Dosing Mistakes

The recurring errors are predictable: starting at or above 1.75 mg with no tolerance for the nausea, taking a first dose right before a planned encounter instead of calibrating timing, re-dosing the same day to chase an effect and stacking the pressor response, and ignoring blood-pressure contraindications. PT-141 is an on-demand tool with a low monthly ceiling; treating it like a daily peptide is the fastest way to a bad experience.